1. Campochiaro C, Tomelleri A, Cavalli G, Berti A, Dagna L. Erdheim-Chester disease. Eur J Intern Med. 2015; 26:223–9.
Article
2. Lim J, Kim KH, Suh KJ, et al. A unique case of Erdheim-Chester disease with axial skeleton, lymph node, and bone marrow involvement. Cancer Res Treat. 2016; 48:415–21.
Article
3. Bindra J, Lam A, Lamba R, VanNess M, Boutin RD. Erdheim-Chester disease: an unusual presentation of an uncommon disease. Skeletal Radiol. 2014; 43:835–40.
Article
4. Pavlidakey PG, Mohanty A, Kohler LJ, Meyerson HJ. Erdheim-chester disease associated with marginal zone lymphoma and monoclonal proteinemia. Case Rep Hematol. 2011; 2011:941637.
Article
5. Haroche J, Amoura Z, Wechsler B, Veyssier-Belot C, Charlotte F, Piette JC. Erdheim-Chester disease. Presse Med. 2007; 36:1663–8.
6. Sheu SY, Wenzel RR, Kersting C, Merten R, Otterbach F, Schmid KW. Erdheim-Chester disease: case report with multisystemic manifestations including testes, thyroid, and lymph nodes, and a review of literature. J Clin Pathol. 2004; 57:1225–8.
Article
7. Ivan D, Neto A, Lemos L, Gupta A. Erdheim-Chester disease: a unique presentation with liver involvement and vertebral osteolytic lesions. Arch Pathol Lab Med. 2003; 127:e337–9.
Article
8. Diamond EL, Dagna L, Hyman DM, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014; 124:483–92.
Article
9. Cha YJ, Yang WI, Park SH, Koo JS. Rosai-Dorfman disease in the breast with increased IgG4 expressing plasma cells: a case report. Korean J Pathol. 2012; 46:489–93.
Article
10. Haroche J, Amoura Z, Charlotte F, et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood. 2008; 111:5413–5.
Article
11. Arnaud L, Hervier B, Néel A, et al. CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011; 117:2778–82.
12. Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016; 127:2672–81.
Article
13. Hervier B, Haroche J, Arnaud L, et al. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood. 2014; 124:1119–26.
14. Emile JF, Diamond EL, Hélias-Rodzewicz Z, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014; 124:3016–9.
15. Munoz J, Janku F, Cohen PR, Kurzrock R. Erdheim-Chester disease: characteristics and management. Mayo Clin Proc. 2014; 89:985–96.
Article
16. Tzoulis C, Schwarzlmuller T, Gjerde IO, et al. Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. BMC Res Notes. 2015; 8:171.
Article
17. Nordmann TM, Juengling FD, Recher M, et al. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations. Blood. 2017; 129:879–82.
18. Cohen-Aubart F, Maksud P, Saadoun D, et al. Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. Blood. 2016; 127:1509–12.
Article
19. Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol. 2010; 28:e633–6.
Article
20. Haroche J, Cohen-Aubart F, Rollins BJ, et al. Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncol. 2017; 18:e113–25.
Article